Published in final edited form as:

Psychoneuroendocrinology. 2019 April ; 102: 114–120. doi:10.1016/j.psyneuen.2018.12.002.

Altered overnight levels of pro-inflammatory cytokines in men and women with posttraumatic stress disorder

Andreas Küffer^{1,2,*}, Laura D. Straus^{1,2,3,*}, Aric A. Prather², Sabra S. Inslicht^{1,2,4}, Anne Richards^{1,2}, Judy K. Shigenaga^{1,2}, Erin Madden¹, Thomas J. Metzler¹, Thomas C. Neylan^{1,2,4,**}, and Aoife O'Donovan^{1,2,4,**}

¹San Francisco Veterans Affairs Medical Center. San Francisco, CA, USA

²Department of Psychiatry, University of California, San Francisco. San Francisco, CA, USA

³Mental Illness Research Education and Clinical Centers, San Francisco VA Healthcare System. San Francisco, CA, USA

⁴Northern California Institute for Research and Education. San Francisco, CA, USA

Abstract

Background: Posttraumatic stress disorder (PTSD) is associated with disturbed sleep and elevated levels of pro-inflammatory cytokines, including interleukin-6 (IL-6) and tumor necrosis factor- α (TNF- α). Studies in animals and healthy humans have also shown that disrupted sleep elevates pro-inflammatory cytokines, including IL-6 and TNF- α . A better understanding of overnight cytokine levels and sleep might shed light on possible mechanisms for elevated inflammation in PTSD. Thus, we investigated overnight levels of IL-6 and TNF- α in individuals with and without PTSD while recording sleep polysomnography (PSG).

Method: Serum samples were collected from otherwise healthy, medication-free participants with chronic PTSD ($n=44$; 50% female; M age=30.34 $\pm$ 8.11) and matched controls ($n=49$; 53% female; M age=30.53 $\pm$ 6.57) during laboratory PSG. Levels of IL-6 and TNF- α were measured at hours 0, 2, 4, 6, and 8 after typical sleep onset time using serial serum samples. Plasma IL-6 and TNF- α levels were quantified using enzyme-linked immunosorbent assays.

Results: Growth model analysis indicated a significant group by time interaction for IL-6 ($t[247] = -2.92$, $p = .005$) and a significant *group* by *sex* by *time* interaction for TNF- α ($t[275] = 2.02$, $p = .04$). PTSD positive men and women initially had higher IL-6 and TNF- α at sleep onset, but not at the end of their sleep cycle. Men with PTSD showed a peak of TNF- α at the end of the sleep

*Corresponding Author: Laura D. Straus, PhD, 4150 Clement St (116P), San Francisco, CA 94121, Laura.Straus@ucsf.edu.

*AK and LDS contributed equally to this work

**TN and AO contributed equally to this work

CRedit author statement

AK: Conceptualization, Formal Analysis, Writing – Original Draft. LDS: Writing – Original Draft. AAP, SSI, and AR: Writing-Reviewing and Editing. JS and EM: Data Curation. TJM: Methodology, Software, Writing – Reviewing and Editing. TCN: Funding Acquisition, Conceptualization, Supervision, Writing – Reviewing and Editing. AO: Conceptualization, Supervision, Writing – Reviewing and Editing.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

cycle, whereas male control subjects demonstrated an inverted U-shaped profile. There were no significant differences in TNF- α levels overnight between women with and without PTSD.

Conclusion: To our knowledge, this is the largest study to examine IL-6 overnight in a PTSD sample and the first study to examine overnight TNF- α in PTSD. Overnight IL-6 and TNF- α levels may be altered in individuals with PTSD compared to those without PTSD, and TNF- α trajectories also differed by sex. The current findings highlight the need to consider sex, sleep, time of day, and circadian variation when examining inflammation in PTSD. Additional research in broader study samples will be necessary to clarify associations between disrupted sleep, cytokines, and increased risk for disease in PTSD.

Keywords

Sleep; Cytokines; Inflammation; Posttraumatic stress disorder; Sex differences

Introduction

Posttraumatic Stress Disorder (PTSD) is a debilitating condition with a lifetime prevalence of approximately 8% (Kessler et al., 1995). In addition to severely impairing psychological wellbeing, PTSD is associated with increased risk for cardiovascular, autoimmune and metabolic disorders, and premature mortality (Boscarino, 2006; Cohen et al., 2009, O'Donovan et al., 2015). Inflammation can drive the development of multiple physical diseases and has been proposed as a mechanism linking PTSD with ill health (O'Donovan, et al., 2012). Though studies differ with respect to methodology (Hussein et al., 2017), numerous studies and a meta-analysis have confirmed that individuals with PTSD tend to exhibit elevated levels of inflammatory markers, including levels of the pro-inflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF- α ; Gill, Vythilingam, & Page, 2008; Lindqvist et al., 2014; Passos et al., 2015), as well as other inflammatory markers such as interferongamma (IFN- γ) and high-sensitivity C-reactive protein (Bruenig et al., 2018; Lindqvist et al., 2017). Additionally, certain treatment strategies, such as psychopharmacological agents (Kenis & Maes, 2002) as well as psychotherapy (Himmerich et al., 2016) can lead to changes in levels of inflammatory markers. However, people with PTSD are a highly heterogeneous group and not all individuals with PTSD display elevated inflammation (Söndergaard, Hansson, & Theorell, 2004). Thus, identifying the specific symptoms of PTSD associated with inflammatory activity could be a first step towards designing interventions that reduce inflammation in PTSD.

Most individuals with PTSD exhibit substantial sleep disturbance, in the form of insomnia and frequent nightmares (Neylan et al., 1998). Objective studies of sleep in PTSD have shown decreased sleep continuity (Mellman et al., 1997) decreased slow-wave sleep (Kobayashi, Boarts, & Delahanty, 2007; Richards et al., 2013) and alterations in rapid eye movement (REM) sleep (Breslau et al., 2004). However, objective sleep disturbance in PTSD appears to differ by sex; women with PTSD show more REM sleep than controls (Otte et al., 2007; Richards et al., 2013). Disrupted sleep in the early aftermath of trauma is associated with worse subsequent clinical symptoms (Mellman, et al., 2002), indicating a potential role of sleep as a mechanism of PTSD symptoms. Disrupted sleep is also

associated with poor physical health outcomes in PTSD (Boyko et al., 2013), indicating a potential role for sleep in increasing physical disease risk in this population.

Research in healthy controls and other sleep-disordered groups indicates that sleep and inflammation are closely intertwined. Some studies show sleep disruption leads to increased concentrations of both IL-6 and TNF- α (Irwin et al., 2006), and a large meta-analytic study showed a significant association of short sleep with higher levels of IL-6 when sleep was measured objectively (Irwin, Olmstead, & Carroll, 2016). Circadian release of TNF- α has also been shown to be disrupted in sleep apnea patients, another group with considerable sleep disturbance (Entzian et al., 1996). PTSD-related sleep disturbance, therefore, could plausibly promote the production of pro-inflammatory cytokines during the night and thereby increase risk for disease. Given that elevated levels of pro-inflammatory cytokines may feed back to the nervous system to further interrupt sleep, particularly delta sleep (Redwine, Hauger, Gillin, & Irwin, 2000), the relationship between PTSD-related sleep disturbance and pro-inflammatory cytokines may be bidirectional.

Despite the evidence for an interrelationship between disrupted sleep and elevated cytokines in PTSD, few studies have examined this directly by studying overnight trajectories of pro-inflammatory cytokines in people with PTSD compared to controls. One study (Gill et al., 2010) examined nine participants with PTSD comorbid with major depressive disorder, nine participants with only PTSD, and 14 non-traumatized control subjects, comparing these three groups on IL-6 levels overnight. In this sample, participants with major depressive disorder and PTSD had significantly higher mean levels of IL-6 than participants in either of the other two groups. Furthermore, peak overnight IL-6 levels correlated significantly with PTSD symptomatology, indicating that people with more severe PTSD showed elevated IL-6 concentrations. These findings support the notion that PTSD is associated with elevated overnight cytokine levels. However, this study did not examine differences in overnight IL-6 by sex and it had a relatively small sample size in each group. Given sex differences in both objective sleep in PTSD (Richards et al., 2013) and associations between sleep and markers of inflammation (Suarez, 2008; Prather et al., 2013), the relationship between disrupted sleep and cytokine production may differ in men and women. To our knowledge, no studies have compared overnight concentrations of TNF- α in people with and without PTSD or examined trajectories of any cytokine overnight.

In the present study, we assessed overnight trajectories for IL-6 and TNF- α in sex- and age-matched adults with and without PTSD. We expected to observe elevated IL-6 and TNF- α concentrations across the night in people with PTSD compared to healthy controls. We also expected that overnight IL-6 and TNF- α would be related to total sleep time such that participants with the shortest sleep duration would show the highest levels of both cytokines.

Methods

Study Participants

Our sample included 85 participants recruited as part of a larger study (N = 93) focused on sleep abnormalities in PTSD. We acknowledge that a mean of 54 on the Clinician Administered PTSD Scale (CAPS) is lower than many studies with treatment seeking

patients, which may be due to our inclusion criteria of being medically healthy and on no medication (see below). As detailed in other studies using this sample (e.g., O'Donovan et al., 2011), participants were recruited through ads and flyers distributed in the community as well as in relevant local clinics for the PTSD sample. Eight participants were excluded from the present study due to difficulties in overnight blood collection. In our sample, 43 participants were positively diagnosed with current, chronic PTSD and 42 were sex- and age-matched medically healthy controls (see Table 1). PTSD diagnosis was established via the CAPS (Blake et al., 1995) conducted by trained clinical interviewers. Eligible participants met DSM-IV criteria for PTSD; see Table 2 for clinical characteristics of the sample. Exclusion criteria included a history of traumatic brain injury; presence of neurologic disorders or systemic illness; use of psychiatric, anticonvulsant, antihypertensive, sympathomimetic, steroidal, statin or other prescription medications; obesity as defined by a body mass index of BMI > 30; alcohol abuse or dependence in the prior 2 years; substance abuse or dependence in the previous year; any psychiatric disorder with psychotic features; bipolar disorder or obsessive compulsive disorder. Subjects with extreme morning tendencies (score < 19) and extreme evening tendencies (score > 47) on the Smith Morningness Scale (Smith, Reilly, & Midkiff, 1989) were excluded. For female participants, pregnancy was an exclusion criterion and all were premenopausal (indicated by having at least one menstrual period in the past 12 months) and scheduled during a follicular phase of the menstrual cycle. Further exclusion criteria for control participants included a history of current or lifetime PTSD and a lifetime history of major depressive disorder (MDD) or panic disorder. All participants provided written informed consent before participating in any study procedures and the project was approved by the Committee on Human Research at the University of California, San Francisco.

Procedure

Participants stayed three consecutive nights at the sleep laboratory in a General Clinical Research Center (GCRC; see Richards et al., 2013 for more details). The current study involved data from the second night, after one habituation night in the sleep laboratory. To account for individual variability of sleep onset, participants were asked to report habitual sleep onset (HSO) via 1-week sleep diary prior to the study. HSO was then used as an individual onset for data recording and acted as the starting point of the experiments, as well as a point of reference for this study. Two hours before HSO, a catheter was inserted into an antecubital vein for repeated blood sampling. Whole blood samples were drawn every 15 minutes starting with HSO until 8 hours after HSO. For this study, blood samples from 0, 2, 4, and 6 hours after HSO were used. Furthermore, a last blood draw was added between 7AM and 10AM after habitual waking time, marking the last timepoint in our analyses.

Measures

PTSD diagnosis: Lifetime and current PTSD were assessed with the Clinician Administered PTSD Scale (CAPS), a structured interview that corresponds to DSM-IV criteria for PTSD (Blake et al., 1995). The CAPS is a 30-item scale that assesses the frequency and intensity of re-experiencing, avoidance, and hyperarousal symptoms of PTSD. Diagnosis of PTSD was based on symptoms experienced in the previous month associated with the subject's self-identified worst traumatic event. Other psychiatric

disorders were assessed by administration of the Structured Clinical Interview for DSM-IV (First et al., 1995).

Cytokines: The human IL-6 Quantikine high sensitivity enzyme-linked immunosorbent assay (hsELISA) and human TNF- α Quantikine hsELISA were used to measure IL-6 and TNF- α respectively (R&D Systems, USA). The lower limits of detection were 0.17 pg/ml for IL-6 and 0.62 pg/ml for TNF- α . Where duplicates differed more than 20%, samples were repeated in duplicate. Intra-assay coefficients of variation were <10% for both IL-6 and TNF- α . One sample had an IL-6 level below the lowest detectable limit of the assays, and 19 had TNF- α levels below the detectable limit; these samples were all recoded as being one unit below the lowest detectable limit.

Total sleep time: As previously described in (Richards et al. 2013), polysomnography recordings were obtained with ambulatory polysomnography (Nihon Kohden Trackit Ambulatory Recording System) in accordance with standardized guidelines (Rechtschaffen, 1968). Pass Plus was utilized for both visual scoring and quantitative EEG analysis of the digitized polysomnography data. Visual scoring was conducted by a highly experienced registered polysomnography technician, who classified all 30-second epochs in every sleep record as wake; stages 1, 2, 3; REM; or movement using current AASM criteria (AASM, 2007). Sleep onset was defined as the first minute of eight consecutive minutes of stage 2 sleep with no more than 2 intervening minutes of stage 1 sleep or minutes awake. Total sleep time was defined by time spent in epochs scored as NREM stages 1 through 3 and stage REM over a time window of ten hours after HSO.

Covariates: Over and beyond the described variables of interest, biological sex (“female” vs “male”) and age, as well as total hours of sleep, entered the analyses of this study as covariates. Given that there was a strong association between PTSD status and body mass index (BMI), BMI was also added as a covariate.

Statistical analyses

Multilevel modeling was used to assess growth curve analyses on the trajectories of the inflammatory responses for each participant, with two-hour cytokine measurements nested within participants. Growth curve modeling was conducted as implemented in the ‘nlme’ library of R (Pinheiro et al., 2014). In all analyses, time was treated as a within-subject continuous variable, group, sex and the covariates as between-subject variables, and the two inflammatory marker responses of IL-6 and TNF- α served as the outcome variables. For all analyses, we modeled time with a quadratic effect in order to account for the non-linear trajectories of nocturnal cytokine levels previously reported in other studies (Cuesta et al., 2016; Nilsson et al., 2016). Since time was not centered, the intercept represented HSO for each participant and the beginning of the growth curve.

Backward model selection was performed by contrasting the deviance of a complex model with that of a simple model using a log-likelihood test (Bliese & Ployhart, 2002). Model parameters were estimated using restricted maximum likelihood. If the complex model fitted the data significantly better than the simple model, we retained the complex model. When

indicated by the model-selection procedure, a random participant intercept and/or slope were included in the model. Secondly, we determined whether a linear, quadratic or cubic time effect fitted the data best. As suggested by Bliese and Ployhard (2002), we then added a more complex error structure (i.e. accounting for autocorrelation or heteroscedasticity) to the models, if model comparison indicated significant differences. Post-hoc contrasts were analyzed with the 'LSMEANS' library of R and multiple comparisons were corrected with false discovery rate (FDR; Benjamini & Hochberg, 1995) with a p -value of 0.05.

In order to achieve normal distribution for IL-6 and TNF- α , natural log transformations were conducted on both biological measures (see Table 1 for IL-6 and TNF- α levels for both the PTSD and control groups, expressed in log-transformed units). Visual inspection indicated that the two transformed variables were normally distributed. To control for multivariate outliers, we use Mahalanobis distance to identify influenceable individuals (Hadi, 1992). As a consequence, data of three participants were deemed influential and subsequently dismissed from the final analyses.

Results

provides an overview of the demographic information of the $N = 85$ participants by group. There was a significant group difference in BMI ($t[79.80] = -2.71$; $p = .01$), driven by a lower mean BMI of controls compared to PTSD-positive participants. Groups also differed in ethnicity ($\chi^2[4] = 14.62$; $p = .006$), with the control group having a higher frequency of Caucasians compared to the PTSD group. Bivariate Pearson correlations revealed no significant associations among the continuous covariates and mean overnight cytokine levels. However, there was an association between the participants age and BMI, indicating that older participants had significantly higher BMI ($r_{\text{age,BMI}} = .27$; $p = .01$), and a marginal positive association between the two mean overnight cytokine levels ($r_{\text{IL-6,TNF-}\alpha} = .20$; $p = .07$; Supplementary Table 1).

We conducted independent samples t -tests for each two-hour segment of the experiment where we compared the cytokine levels between the two groups. None of these t -tests indicated a significant group differences between these levels across all timepoints (see Figure 1).

Nocturnal IL-6 Trajectory

Our analyses showed a substantial dependency amongst IL-6 responses within subjects ($\text{ICC} = .46$). To account for within-person change of IL-6, we continued with specifying our growth model. Model specification indicated that the within-subject factor time predicted IL-6 responses best when squared. Furthermore, our model selection process identified a random intercept and slope model for IL-6 responses, while accounting for heteroscedasticity.

To test our first assumption, that nocturnal IL-6 levels would be different between controls and participants with PTSD, we added group as a fixed effect to our above specified model. In this model, *group* interacted significantly with both *time* ($B = 0.16$, $\text{SE} = 0.07$, $p = .02$) and *time*² ($B = -0.02$, $\text{SE} = 0.01$, $p = .01$). To test our hypothesis that *group* and *sex*

accounted for a significant amount of variability in *IL-6 levels* over the course of the sleep cycle, we added *sex* to our specified random intercept and slope model. In this model, none of the interactions involving *sex* were significant (all $p > .21$), leading us to treat *sex* as a covariate in subsequent models. Controlling for *age*, *sex* and *BMI*, the IL-6 model still indicated a significant 2-way interaction of $group \times time$ ($B = 0.19$, $SE = 0.06$, $p = .003$) and $group \times time^2$ ($B = -0.02$, $SE = 0.01$, $p < .001$). Figure 2 shows that IL-6 levels increased after HSO for both groups and dropped again approximately after 4 hours, following an inverted U-shaped trajectory of IL-6 levels for both groups. This trajectory was distinctively more pronounced in the PTSD group than in the control group, and the control group showed an almost flat slope (see Table 3).

FDR adjusted follow-up analyses examined the differences in predicted IL-6 level at each time point compared to each other time point, based on the fully adjusted model. Within the PTSD group, all pairwise contrasts between time points were statistically significant, showing the robustness of changes over the night (see Table 3). No pairwise comparisons between time points were significant within the control group, indicating the relative stability of IL-6 levels in this group.

In order to assess if our findings were independent from *total sleep time*, we computed a final model that adjusted for the total amount of sleep within a ten-hour window. This model revealed the same $group \times time$ interactions (i.e. linear and quadratic), but no significant effect of *total sleep time* ($p = .14$).

Nocturnal TNF- α Trajectory

Measurements of TNF- α were dependent within subjects ($ICC = .66$). Subsequent model comparison indicated that a random intercept and slope model fitted the TNF- α responses best. Furthermore, model specification indicated that we did not have to account for autocorrelation, but again for heteroscedasticity.

Following the same process as described for IL-6, we started by adding *group* to the model. In this model, we found a significant $group \times time^2$ ($B = 0.007$, $SE = 0.002$, $p = .01$) and a significant $group \times time$ interaction ($B = -0.04$, $SE = 0.02$, $p = .04$). We then proceeded by adding *sex* to our model. This analysis revealed a 3-way interaction between *group*, *sex* and $time^2$ ($B = 0.009$, $SE = 0.004$, $p = .05$). The analysis also revealed significant $sex \times time^2$ interaction ($B = -0.01$, $SE = 0.003$, $p = .02$) and a $sex \times time$ interaction ($B = -0.07$, $SE = 0.03$, $p = .01$), while all the other effects were not significant (all $p > .23$). Adding the covariates *age* and *BMI* to the model did not change any of the above-mentioned results.

To better examine our marginal 3-way interaction between *group*, *sex* and $time^2$, we ran our final models stratified by group. The model with only *sex* and *time* of the control sample showed a significant interaction between *sex* and the linear effect of *time* ($B = 0.06$, $SE = 0.03$, $p = .02$), as well as with a quadratic effect of *time* ($B = -0.01$, $SE = 0.003$, $p = .01$). For the PTSD group, the interaction effects were not significant (both $p > .55$). But there was a significant quadratic effect of *time* ($B = 0.005$, $SE = 0.002$, $p = .02$) and a trend towards a linear effect of *time* ($B = -0.04$, $SE = 0.002$, $p = .06$); the effect of *sex* was not significant ($p = .64$). Adding the covariates *age* and *BMI* to both models did not substantially change the

estimates for either group, but BMI was significantly associated with TNF- α levels ($B = 0.02$, $SE = 0.01$, $p = .03$; see Table 3).

The 3-way interaction of $time^2$, $group$ and sex is reflected in an inverted U-shaped trajectory for TNF- α levels of the male control participants over the course of the 8-hour period, peaking around 4 hours after self-reported HSO, while the other three subsamples (control female participants and PTSD positive females and males) followed a U-shaped trajectory (see Figure 3). But while the TNF- α levels of control males followed a pronounced slope and dropped below the initial level (measured at hour 0), TNF- α levels for female controls remained largely unchanged. Both men and women in the PTSD positive group had higher TNF- α levels after 8 hours, while this effect was more pronounced in PTSD positive males and flat in PTSD positive females.

As illustrated by Figure 3, FDR-adjusted follow-up analysis of the predicted means from the fully adjusted model within the control male subsample indicated that the increase of TNF- α levels from hour 0 to 2 was marginally significant, while the drops between hour 4 to 6 and 6 to 8 were significant. The drop from hour 0 to 8 was marginally significant. Within the PTSD positive male subsample, the elevations of hour 4 to 6, the elevation of hour 6 to 8, and the overall increase from hour 0 to hour 8 were significant. All comparisons within the female subsamples were not significant, indicating no significant within-group changes.

Effects of sleep: We finally also assessed if the TNF- α was independent from *total sleep time* and computed a sleep-adjusted model. Adding the sleep measure resulted in non-significant 3-way interactions (both $ps > .11$), albeit without any impact on effect sizes derived from our original models. The $sex \times time$ ($B = 0.07$, $SE = 0.03$, $p = .02$) and $sex \times time^2$ ($B = -0.01$, $SE = 0.003$, $p = .01$) interactions were unchanged, while none of the previous main effects were significant (all $ps > .16$). *Total sleep time* had a significant positive effect ($B = 0.001$, $SE = 0.0005$, $p = .02$), indicating that more sleep was associated with higher peak TNF- α levels overnight.

Discussion

The current study examined levels of pro-inflammatory cytokines overnight in a sample of PTSD-positive adults in comparison to age- and sex-matched controls. Broadly, our results showed no significant differences between the PTSD-positive participants and controls at any single timepoint. However, the groups did differ on their overnight trajectories of cytokine levels. With regard to IL-6, the PTSD-positive participants showed more variation overnight, with an exaggerated inverted U-shaped curve consisting of lower IL-6 levels than the controls at the start and end of the night and higher midpoint IL-6 levels four hours after habitual sleep onset. Regarding TNF- α , PTSD-positive participants showed elevated cytokine levels at the end of the night in comparison to controls, though the trajectory of TNF- α levels overnight differed by sex. While the male control participants showed an inverted U-shaped trajectory of TNF- α levels overnight, all three other groups showed flatter U-shaped trajectories of TNF- α overnight.

Although the current study did not support our initial hypothesis that PTSD-positive participants would show elevated cytokines overnight, they did differ from healthy controls when considering the overall shape of the trajectories of cytokine levels over the course of the night. For example, the overnight peak in IL-6 was higher in the PTSD sample in comparison to controls, while TNF- α was elevated in comparison to the controls 8 hours after habitual sleep onset. Additionally, the men without PTSD showed altered TNF- α trajectories overnight in comparison to all other groups. All of these differences suggest alterations in time course of pro-inflammatory activity overnight in PTSD, indicating the importance of considering time of day and trajectories of responses when trying to understand altered inflammatory activity in PTSD.

Based on previous studies showing elevated inflammatory activity in PTSD compared to controls (Passos et al., 2015), disrupted sleep in PTSD (Kobayashi, Boarts, & Delahanty, 2007), and elevated cytokines associated with sleep disruption (Irwin, Olmstead, & Carroll, 2016), we expected overall overnight elevations in both IL-6 and TNF- α in PTSD. There may be a number of reasons why results from the current study were not broadly consistent with this pattern. Importantly, there is a high degree of inter-individual variability in both sleep disruption (Straus et al., 2015) and inflammatory activity in PTSD (O'Donovan et al., 2017), with several studies suggesting that not all PTSD patients show sleep disruption or inflammation. Additionally, previous research has suggested that elevated cytokine levels overnight is associated with severity of PTSD symptoms (Gill et al., 2010). The current study selected for physically healthy, medication-free younger adults with PTSD. Interestingly, PTSD severity in our sample was much lower in comparison to the sample recruited by Gill and colleagues (mean CAPS score = 54 versus 82 in the comorbid PTSD +depression group from Gill et al.). Selection criteria for the current study may have constrained our sample to participants with relatively less severe symptoms.

There are several limitations of the current study worth noting. First, our small sample size limits the ability to draw strong conclusions. Importantly, as stated above, the current study consisted of physically healthy, non-obese, non-medicated younger adults with PTSD, which allowed us to examine associations of PTSD with inflammation independent of some of these potential confounds. However, given that PTSD is associated with increased risk for a number of physical diseases, including cardiovascular, autoimmune, and metabolic disorders (Boscarino, 2006; Cohen et al., 2009; O'Donovan et al., 2015), the current sample may not be generalizable to a more representative sample of PTSD patients. Though the samples were matched based on age and sex, there are a number of ways in which participants with PTSD differed from control participants (trauma exposure, type of trauma, veteran status, ethnicity, smoking), so future studies should attempt to control for these confounding factors. The current study only included analyses of TNF- α and IL-6, though other inflammatory markers such as IFN- γ and high-sensitivity C-reactive protein may also be elevated in PTSD (Breunig et al., 2018; Lindqvist et al., 2017). In addition, both TNF- α production and receptor levels may be modified by treatments such as psychotherapy (Himmerich et al., 2016). Though the current study excluded medication use, no information was collected about IL-6 or TNF- α receptors, and no information is available about prior history of psychotherapy use in the sample. Future studies should more closely examine these associations. Additionally, the current study was constrained to examining a single

night of data collection. Finally, the current study sampled cytokines at only five timepoints overnight, only three of which occurred during the habitual sleep period, limiting the opportunity to examine trajectories at a more fine-grained level of detail, including examining detailed relationships between sleep architecture/sleep cycles and their relationship to cytokine levels during the sleep period. Future studies using more frequent sampling during the sleep period will be able to examine these relationships more thoroughly.

To our knowledge, this is the largest study to examine IL-6 overnight in a PTSD sample and the first study to examine overnight TNF- α in PTSD. The current findings demonstrate altered overnight levels of pro-inflammatory markers in men and women with PTSD in comparison to healthy control participants. Additional research in broader study samples will be necessary to continue to examine relationships between disrupted sleep, cytokines, and increased risk for disease in PTSD. The current findings highlight the need to consider sex, sleep, time of day, and circadian variation when examining inflammation in PTSD.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding: This work was supported by the National Institutes of Health [TCN: 5R01MH073978-04, AO: K01MH109871], University of California, San Francisco Hellman Fellowship, and the Mental Illness Research and Education Clinical Center of the US Veterans Health Administration. During his work, AK was funded by the Swiss National Science Foundation through an Early Postdoctoral Mobility Grant. The authors declare no conflicts of interest.

References

- Benjamini Y, & Hochberg Y, 1995 Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J. Royal Stat. Soc. Series B (Methodological)*, 289–300.
- Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, & Keane TM, 1995 The development of a clinician-administered PTSD scale. *J. Trauma. Stress*, 8, 75–90. [PubMed: 7712061]
- Bliese PD, & Ployhart RE, 2002 Growth modeling using random coefficient models: Model building, testing, and illustrations. *Organizational Res. Methods*, 5, 362–387.
- Boscarino JA, 2006 Posttraumatic stress disorder and mortality among US Army veterans 30 years after military service. *Ann. Epidemiology*, 16, 248–256.
- Boyko EJ, Seelig AD, Jacobson IG, Hooper TI, Smith B, Smith TC, ... & Millennium Cohort Study Team, 2013 Sleep characteristics, mental health, and diabetes risk: a prospective study of US military service members in the Millennium Cohort Study. *Diabetes Care*, 36, 3154–3161. [PubMed: 23835691]
- Breslau N, Roth T, Burduvali E, Kapke A, Schultz L, & Roehrs T, 2004 Sleep in lifetime posttraumatic stress disorder: a community-based polysomnographic study. *Arch. Gen. Psychiatry*, 61, 508–516. [PubMed: 15123496]
- Bruenig D, Mehta D, Morris CP, Lawford B, Harvey W, Young RM, & Voisey J (2018). Correlation between interferon γ and interleukin 6 with PTSD and resilience. *Psychiatry Res.*, 260, 193–198. [PubMed: 29202383]
- Cohen BE, Marmar C, Ren L, Bertenthal D, & Seal KH, 2009 Association of cardiovascular risk factors with mental health diagnoses in Iraq and Afghanistan war veterans using VA health care. *JAMA*, 302, 489–492. [PubMed: 19654382]

- Cuesta M, Boudreau P, Dubeau-Laramée G, Cermakian N, & Boivin DB, 2016 Simulated night shift disrupts circadian rhythms of immune functions in humans. *J. Immunology*, 196, 2466–2475. [PubMed: 26873990]
- Entzian P, Linnemann K, Schlaak M, & Zabel P, 1996 Obstructive sleep apnea syndrome and circadian rhythms of hormones and cytokines. *Am. J. Respiratory Crit. Care Med*, 153, 1080–1086.
- First MB, Spitzer RL, Gibbon MWJB, & Williams JB, 1995 Structured clinical interview for DSM-IV axis I disorders. New York: New York State Psychiatric Institute.
- Gill J, Luckenbaugh D, Charney D, & Vythilingam M, 2010 Sustained elevation of serum interleukin-6 and relative insensitivity to hydrocortisone differentiates posttraumatic stress disorder with and without depression. *Biol. Psychiatry*, 68, 999–1006. [PubMed: 20951370]
- Gill J, Vythilingam M, & Page GG, 2008 Low cortisol, high DHEA, and high levels of stimulated TNF- α , and IL-6 in women with PTSD. *J. Trauma. Stress*, 21, 530–539. [PubMed: 19107725]
- Hadi AS, 1992 Identifying multiple outliers in multivariate data. *J. Royal Stat. Soc. Series B (Methodological)*, 761–771.
- Himmerich H, D Willmund G, Zimmermann P, Wolf JE, H Bühler A, C Kirkby K, ... & Wesemann U. (2016). Serum concentrations of TNF-a and its soluble receptors during psychotherapy in German soldiers suffering from combat-related PTSD. *Psychiatria Danub.*, 28, 3, 293–298.
- Hussein S, Dalton B, D Willmund G, & Ibrahim MA (2017). A systematic review of tumor necrosis factor-a in post-traumatic stress disorder: Evidence from human and animal studies. *Psychiatria Danubina*, 29, 4, 407–420. [PubMed: 29197197]
- Iber C, Ancoli-Israel S, Chesson A, & Quan SF, 2007 authors; for the American Academy of Sleep Medicine. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications.
- Irwin MR, Olmstead R, & Carroll JE, 2016 Sleep disturbance, sleep duration, and inflammation: a systematic review and meta-analysis of cohort studies and experimental sleep deprivation. *Biol. Psychiatry*, 80, 40–52. [PubMed: 26140821]
- Irwin MR, Wang M, Campomayor CO, Collado-Hidalgo A, & Cole S, 2006 Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. *Arch. Intern. Med*, 166, 1756–1762. [PubMed: 16983055]
- Kenis G, & Maes M (2002). Effects of antidepressants on the production of cytokines. *Internat. J. Neuropsychopharmacology*, 5, 4, 401–412.
- Kessler RC, Sonnega A, Bromet E, Hughes M, & Nelson CB, 1995 Posttraumatic stress disorder in the National Comorbidity Survey. *Arch. Gen. Psychiatry*, 52, 1048–1060. [PubMed: 7492257]
- Kobayashi I, Boarts JM, & Delahanty DL, 2007 Polysomnographically measured sleep abnormalities in PTSD: a meta-analytic review. *Psychophysiology*, 44, 660–669. [PubMed: 17521374]
- Lindqvist D, Dhabhar FS, Mellon SH, Yehuda R, Grenon SM, Flory JD, ... & Reus, VI. (2017). Increased pro-inflammatory milieu in combat related PTSD—a new cohort replication study. *Brain Behav. Immun*, 59, 260–264. [PubMed: 27638184]
- Lindqvist D, Wolkowitz OM, Mellon S, Yehuda R, Flory JD, Henn-Haase C, ... & Makotkine I, 2014 Proinflammatory milieu in combat-related PTSD is independent of depression and early life stress. *Brain Behav. Immun*, 42, 81–88. [PubMed: 24929195]
- Mellman TA, Bustamante V, Fins AI, Pigeon WR, & Nolan B, 2002 REM sleep and the early development of posttraumatic stress disorder. *Am. J. Psychiatry*, 159, 1696–1701. [PubMed: 12359675]
- Mellman TA, Nolan B, Hebding J, Kulick-Bell R, & Dominguez R, 1997 A polysomnographic comparison of veterans with combat-related PTSD, depressed men, and non-ill controls. *Sleep*, 20, 46–51. [PubMed: 9130334]
- Neylan TC, Lenoci M, Maglione ML, Rosenlicht NZ, Metzler TJ, Otte C, ... & Marmar, CR., 2003 Delta sleep response to metyrapone in post-traumatic stress disorder. *Neuropsychopharmacology*, 28, 1666. [PubMed: 12799616]
- Neylan TC, Marmar CR, Metzler TJ, Weiss DS, Zatzick DF, Delucchi KL, ... & Schoenfeld, FB, 1998 Sleep disturbances in the Vietnam generation: findings from a nationally representative sample of male Vietnam veterans. *Am. J. Psychiatry*, 155, 929–933. [PubMed: 9659859]

- Nilsson G, Lekander M, Åkerstedt T, Axelsson J, & Ingre M, 2016 Diurnal variation of circulating interleukin-6 in humans: a meta-analysis. *PloS One*, 11, e0165799. [PubMed: 27832117]
- O'Donovan A, Ahmadian AJ, Neylan TC, Pacult MA, Edmondson D, & Cohen BE, 2017 Current posttraumatic stress disorder and exaggerated threat sensitivity associated with elevated inflammation in the Mind Your Heart Study. *Brain Behav. Immun*, 60, 198–205. [PubMed: 27765647]
- O'Donovan A, Cohen BE, Seal KH, Bertenthal D, Margaretten M, Nishimi K, & Neylan TC, 2015 Elevated risk for autoimmune disorders in Iraq and Afghanistan veterans with posttraumatic stress disorder. *Biol. Psychiatry*, 77, 365–374. [PubMed: 25104173]
- O'Donovan A, Epel E, Lin J, Wolkowitz O, Cohen B, Maguen S, ... & Neylan TC. (2011). Childhood trauma associated with short leukocyte telomere length in posttraumatic stress disorder. *Biol. Psychiatry*, 70, 5, 465–471. [PubMed: 21489410]
- O'Donovan A, Slavich GM, Epel ES, & Neylan TC, 2013 Exaggerated neurobiological sensitivity to threat as a mechanism linking anxiety with increased risk for diseases of aging. *Neurosci. Biobehav. Rev*, 37, 96–108. [PubMed: 23127296]
- Otte C, Lenoci M, Metzler T, Yehuda R, Marmar CR, & Neylan TC, 2007 Effects of metyrapone on hypothalamic-pituitary-adrenal axis and sleep in women with post-traumatic stress disorder. *Biol. Psychiatry*, 61, 952–956. [PubMed: 17336940]
- Passos IC, Vasconcelos-Moreno MP, Costa LG, Kunz M, Brietzke E, Quevedo J, ... & Kauer-Sant'Anna M, 2015 Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. *The Lancet Psychiatry*, 2, 1002–1012. [PubMed: 26544749]
- Pinheiro J, Bates D, DebRoy S, Sarkar D, R Core Team, 2014 nlme: Linear and Nonlinear Mixed Effects Models_. R package version 3.1-117. Available: <http://CRAN.R-project.org/package=nlme>
- Prather AA, Epel ES, Cohen BE, Neylan TC, & Whooley MA, 2013 Gender differences in the prospective associations of self-reported sleep quality with biomarkers of systemic inflammation and coagulation: Findings from the Heart and Soul Study. *J. Psychiatric Res*, 47, 1228–1235.
- Rechtschaffen A, 1968 A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Public health service.
- Redwine L, Hauger RL, Gillin JC, & Irwin M, 2000 Effects of sleep and sleep deprivation on interleukin-6, growth hormone, cortisol, and melatonin levels in humans. *J. Clin. Endocrinol. & Metabolism*, 85, 3597–3603.
- Richards A, Metzler TJ, Ruoff LM, Inslicht SS, Rao M, Talbot LS, & Neylan TC, 2013 Sex differences in objective measures of sleep in post-traumatic stress disorder and healthy control subjects. *J. Sleep Res*, 22, 679–687. [PubMed: 23763708]
- Smith CS, Reilly C, & Midkiff K, 1989 Evaluation of three circadian rhythm questionnaires with suggestions for an improved measure of morningness. *J. Appl. Psychol*, 74, 728. [PubMed: 2793773]
- Straus LD, Drummond S, Nappi CM, Jenkins MM, & Norman SB, 2015 Sleep variability in military-related PTSD: A comparison to primary insomnia and healthy controls. *J. Trauma. Stress*, 28, 8–16. [PubMed: 25630526]
- Söndergaard HP, Hansson LO, & Theorell T, 2004 The inflammatory markers C-reactive protein and serum amyloid A in refugees with and without posttraumatic stress disorder. *Clinica Chimica Acta*, 342, 93–98.
- Suarez EC, 2008 Self-reported symptoms of sleep disturbance and inflammation, coagulation, insulin resistance and psychosocial distress: evidence for gender disparity. *Brain Behav. Immun*, 22, 960–968. [PubMed: 18328671]

Figure 1.
Barplots of unadjusted, log-transformed cytokine levels over the 5 timepoints by group.
Note. Error bars represent +/- 1 standard errors.

Figure 2. Predicted IL-6 levels of PTSD positive subjects and healthy controls. *Note.* Error bars represent ± 1 standard errors.

Figure 3.
Predicted TNF- α levels of women and men, by PTSD group.
Note. Error bars represent $\pm$ 1 standard errors.

Table 1.

Demographics of controls and PTSD positive participants.

	Control (n = 42)	PTSD (n = 43)	d/p_c	DF	t/X^2	P
Age (M (SD))	30.48 (8.26)	30.63 (6.63)	-0.02	78.48	-0.09	.93
Years of Education (M (SD))	15.38 (2.02)	14.86 (2.23)	0.24	82.55	1.13	.26
BMI (M (SD))	24.45 (3.74)	26.93 (4.69)	-0.59	79.80	-2.71	.01
Total sleep time (M (SD))	774.84 (29.16)	748.63 (36.20)	0.20	73.17	0.88	.38
Clock time of HSO (M (SD))	00:07h (69min)	23:48h (76min)	-0.26	82.61	1.21	.23
Average IL-6 (M In pg/ml (SD))	0.10 (0.80)	0.13 (0.97)	-0.02	80.78	-0.11	.86
Average TNF- α (M In pg/ml (SD))	0.03 (0.35)	0.00 (0.33)	0.07	82.33	0.34	.74
Sex (Male %)	21 (50.00)	22 (51.16)	0.00	1	0.00	>.99
Smoking Status (%)	8 (19.05)	11 (25.58)	0.05	1	0.21	.64
Veteran Status (%)	0 (0)	10 (23.26)				
Ethnicity (%)			0.24	4	14.62	.01
African American	1 (2.38)	5 (11.63)				
Asian	7 (16.67)	2 (4.65)				
Caucasian	31 (73.81)	23 (53.49)				
Hispanic	3 (7.14)	6 (13.95)				
Others	0 (0.00)	7 (16.28)				
Marital Status (%)			0.21	2	7.49	.02
Divorced/Separated	1 (2.38)	8 (18.60)				
Married	6 (14.29)	2 (4.65)				
Single	35 (83.33)	33 (76.74)				

Note. Welch two-sample *t*-test were applied to compare the groups on continuous measures and X^2 -tests were applied to discrete measures. For statistical testing, cytokine measures were log-transformed before entering the analyses to approximate normal distributions. BMI = body mass index; HSO = habitual sleep onset.

Table 2.

Clinical Characteristics.

	Control (<i>n</i> = 42)	PTSD (<i>n</i> = 43)
<i>Trauma-Exposed (<i>n</i> (%))</i>	11 (26.19)	43 (100.00)
<i>Clinician Administered PTSD Scale Total Score (<i>M</i> (<i>SD</i>))</i>	0 (0.00)	54.00 (14.91)
<i>Time Since Trauma (Years (<i>SD</i>))</i>	11.53 (10.20)	9.01 (9.36)
<i>Trauma Type (<i>n</i> (%))</i>		
Combat	0 (0.00)	8 (18.60)
Motor Vehicle Accident	4 (9.52)	0 (0.00)
Physical Violence/Abuse	4 (9.52)	18 (41.86)
Sexual Assault/Abuse	0 (0.00)	16 (37.21)
Sudden/Violent death	2 (4.76)	2 (4.65)
Other	1 (2.38)	5 (11.63)

Note. For trauma type, numbers and percentages overlap because some Criterion A events fit multiple categories. “Other” category included almost drowning (*n* = 1, PTSD group), stalking (*n* = 2, PTSD group), and complications from a medical procedure (*n* = 1, Control group).

Table 3.

Fixed effects of fully adjusted overnight cytokine models by group.

Fully adjusted model for IL-6 overnight levels of control participants							Fully adjusted model for IL-6 overnight levels of PTSD participants						
Parameter	Coefficient (B)	SE	DF	<i>t</i>	<i>P</i>		Parameter	Coefficient (B)	SE	DF	<i>t</i>	<i>P</i>	
Intercept	−0.05	0.72	135	−0.72	.47		Intercept	1.01	0.50	119	−2.03	.04	
<i>Age</i>	0.01	0.01	37	0.68	.50		<i>Age</i>	0.01	0.01	37	1.35	.19	
<i>BMI</i>	0.01	0.03	37	0.20	.84		<i>BMI</i>	0.002	0.02	37	0.11	.92	
<i>Sex (Men)</i>	−0.09	0.20	37	−0.42	.68		<i>Sex (Men)</i>	0.19	0.16	37	1.19	.24	
<i>Time</i>	0.10	0.03	135	3.12	.01		<i>Time</i>	0.31	0.05	119	6.58	.001	
<i>Time</i> ²	−0.01	0.004	135	−2.35	.02		<i>Time</i> ²	−0.04	0.01	119	−6.84	.001	
Fully adjusted model for TNF-α overnight levels of control participants							Fully adjusted model for TNF-α overnight levels of PTSD participants						
Parameter	Coefficient (B)	SE	DF	<i>t</i>	<i>P</i>		Parameter	Coefficient (B)	SE	DF	<i>t</i>	<i>P</i>	
Intercept	0.14	0.27	139	0.52	.60		Intercept	−0.36	0.25	136	−1.43	.16	
<i>Age</i>	−0.001	0.01	35	−0.11	.92		<i>Age</i>	−0.005	0.01	37	−0.87	.39	
<i>BMI</i>	−0.01	0.01	35	−0.68	.50		<i>BMI</i>	0.02	0.01	37	2.22	.03	
<i>Sex (Men)</i>	0.04	0.10	35	0.43	.67		<i>Sex (Men)</i>	−0.13	0.10	37	−1.37	.18	
<i>Time</i>	−0.02	0.02	139	−0.99	.32		<i>Time</i>	−0.04	0.02	136	−1.86	.07	
<i>Time</i> ²	0.002	0.002	139	0.99	.32		<i>Time</i> ²	0.005	0.002	136	2.22	.03	
<i>Sex × Time</i>	0.06	0.03	139	2.36	.02		<i>Sex × Time</i>	0.01	0.03	136	0.50	.62	
<i>Sex × Time</i> ²	−0.01	0.00	139	−3.03	.003		<i>Sex × Time</i> ²	0.000	0.003	136	−0.09	.93	

Note. The coefficients for *Time* entered the models as hours. All cytokine measures were log-transformed before entering the analyses to approximate normal distributions.